Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?

Dig Dis Sci. 2020 Aug;65(8):2158-2160. doi: 10.1007/s10620-020-06283-6.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Biosimilar Pharmaceuticals* / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases* / drug therapy
  • Infliximab / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • Infliximab